GlassScriptPhysician profile
Erik Hasenboehler
NPI 1033380597
$32,303.29
in general payments reported to CMS, 2019-2025
9 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Orthopaedic Trauma provider received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $13K · 2021: $1,103 · 2022: $8,431 · 2023: $8,741 · 2024: $224 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,200 · Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,200.00 |
| Food and Beverage | $950.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $17,654.00 | 2019-2025 | Pro, Axsos, T2 Alpha |
| Medical Device Business Services, INC. | $7,821.52 | 2020 | |
| Synthes Gmbh | $6,524.11 | 2020-2022 | |
| Depuy Synthes Sales INC. | $129.94 | 2019-2020 | |
| Baxter Healthcare | $127.40 | 2023 | Tisseel |
| Polynovo North America LLC | $24.28 | 2022 | |
| Mentor Worldwide LLC | $22.04 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$505,725.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Hasenboehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.